COVID-19-Associated Rhinocerebral Mucormycosis, an Incidental Finding or a Matter of Concern – Mixed-Method Systematic Review

References

• Ciotti M, Ciccozzi M, Terrinoni A, et al. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57(6):365–388. doi:10.1080/10408363.2020.1783198
   PubMed Web of Science ®Google Scholar
• WHO coronavirus (COVID-19) dashboard [Internet]. World Health Organization; 2023. Available from: https://covid19.who.int/. Accessed January 17, 2024.
   Google Scholar
• Vetter P, Vu DL, L’Huillier AG, et al. Clinical features of COVID-19. BMJ. 2020;2020;369.
   Google Scholar
• Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:10.1016/j.jaut.2020.102433
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-5
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Koehler P, Cornely OA, Böttiger BW, et al. COVID‐19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528–534. doi:10.1111/myc.13096
   PubMed Web of Science ®Google Scholar
• Bentvelsen RG, van Arkel AL, Rijpstra TA, et al. Fungal infection during COVID-19: does aspergillus mean secondary invasive aspergillosis? Am J Respir Crit Care Med. 2020;202(6):903–904. doi:10.1164/rccm.202006-2241LE
   PubMed Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34. doi:10.1016/j.cmi.2018.07.011
   PubMed Web of Science ®Google Scholar
• Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009;15 Suppl.5:2–9. doi:10.1111/j.1469-0691.2009.02972.x
   PubMed Web of Science ®Google Scholar
• Yasmin F, Najeeb H, Naeem A, et al. COVID-19 associated mucormycosis: a systematic review from diagnostic challenges to management. Diseases. 2021;9(4):65. doi:10.3390/diseases9040065
   PubMedGoogle Scholar
• Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. doi:10.1016/j.dsx.2021.05.019
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, Pa: Churchill Livingstone; 2010:3257–3269.
   Google Scholar
• Liberati A, Altman DG and Tetzlaff J, et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339(jul21 1), b2700–b2700. 10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar
• Checklist CA, How CS. Critical appraisal skills program; 2018. Available from: https://casp-uk.net/wp-content/uploads/2018/01/CASP-Qualitative-Checklist-2018.pdf. Accessed May 04, 2021.
   Google Scholar
• Critical appraisal tools [Internet]. JBI; 2023. Available from: https://jbi.global/critical-appraisal-tools. Accessed January 17, 2024.
   Google Scholar
• Crone CG, Helweg-Larsen J, Steensen M, et al. Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: mind the diagnostic gap. J Medi Mycol. 2022;32(1):101228. doi:10.1016/j.mycmed.2021.101228
   PubMed Web of Science ®Google Scholar
• Buil JB, van Zanten AR, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Eurosurveillance. 2021;26(23):2100510. doi:10.2807/1560-7917.ES.2021.26.23.2100510
   Web of Science ®Google Scholar
• Malek I, Sayadi J, Lahiani R, et al. Acute bilateral blindness in a young COVID-19 patient with rhino-orbito-cerebral mucormycosis. J Ophthalmic Inflamm Infect. 2021;11:1–4. doi:10.1186/s12348-021-00272-0
   PubMed Web of Science ®Google Scholar
• Arana C, Cuevas Ramírez RE, Xipell M, et al. Mucormycosis associated with COVID‐19 in two kidney transplant patients. Transplant Infect Dis. 2021;23(4):e13652. doi:10.1111/tid.13652
   PubMed Web of Science ®Google Scholar
• Palou EY, Ramos MA, Cherenfant E, et al. COVID-19 associated rhino-orbital mucormycosis complicated by gangrenous and bone necrosis—a case report from Honduras. Vaccines. 2021;9(8):826. doi:10.3390/vaccines9080826
   Web of Science ®Google Scholar
• Riad A, Shabaan AA, Issa J, et al. COVID-19-Associated Mucormycosis (CAM): case-series and global analysis of mortality risk factors. J Fungi. 2021;7(10):837. doi:10.3390/jof7100837
   Web of Science ®Google Scholar
• Aranjani JM, Manuel A, Abdul Razack HI, et al. COVID-19–associated mucormycosis: evidence-based critical review of an emerging infection burden during the pandemic’s second wave in India. PLoS Negl Trop Dis. 2021;15(11):e0009921. doi:10.1371/journal.pntd.0009921
   PubMed Web of Science ®Google Scholar
• Pandiar D, Kumar NS, Anand R, et al. Does COVID 19 generate a milieu for propagation of mucormycosis? Med Hypotheses. 2021;152:110613. doi:10.1016/j.mehy.2021.110613
   PubMed Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26. doi:10.3390/jof5010026
   Web of Science ®Google Scholar
• Chao CM, Lai CC, Yu WL. COVID-19 associated mucormycosis–an emerging threat. J Microbiol Immunol Infect. 2022;55(2):183–190. doi:10.1016/j.jmii.2021.12.007
   PubMedGoogle Scholar
• Rudrabhatla PK, Reghukumar A, Thomas SV. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. Acta Neurol Belg. 2022;2022;1–8.
   Google Scholar
• Malhotra HS, Gupta P, Mehrotra D, et al. COVID-19 associated mucormycosis: staging and management recommendations (Report of a multi-disciplinary expert committee). J Oral Biol Craniofac Res. 2021;11(4):569–580. doi:10.1016/j.jobcr.2021.08.001
   PubMedGoogle Scholar
• Narayanan S, Chua JV, Baddley JW. Coronavirus disease 2019–associated mucormycosis: risk factors and mechanisms of disease. Clinl Infect Dis. 2022;74(7):1279–1283. doi:10.1093/cid/ciab726
   PubMed Web of Science ®Google Scholar
• Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19 -associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021;186(6):739–754. doi:10.1007/s11046-021-00584-8
   PubMed Web of Science ®Google Scholar
• Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM and ISHAM. ECMM/ISHAM recommendations for clinical management of COVID‐19 associated mucormycosis in low‐and middle‐income countries. Mycoses. 2021;64(9):1028–1037. doi:10.1111/myc.13335
   PubMed Web of Science ®Google Scholar
• Sarda R, Swain S, Ray A, et al. COVID-19 -associated mucormycosis: an epidemic within a pandemic. QJM. 2021;114(6):355–356. doi:10.1093/qjmed/hcab165
   PubMed Web of Science ®Google Scholar
• Asdaq SM, Rajan A, Damodaran A, et al. Identifying mucormycosis severity in Indian COVID-19 patients: a nano-based diagnosis and the necessity for critical therapeutic intervention. Antibiotics. 2021;10(11):1308. doi:10.3390/antibiotics10111308
   Google Scholar
• Seidel D, Simon M, Sprute R, et al. Results from a national survey on COVID‐19‐associated mucormycosis in Germany: 13 patients from six tertiary hospitals. Mycoses. 2022;65(1):103–109. doi:10.1111/myc.13379
   PubMed Web of Science ®Google Scholar
• Sharma S, Grover M, Bhargava S, et al. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngology Otol. 2021;135(5):442–447. doi:10.1017/S0022215121000992
   PubMed Web of Science ®Google Scholar
• Bayram N, Ozsaygılı C, Sav H, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol. 2021;65(4):515–525. doi:10.1007/s10384-021-00845-5
   PubMed Web of Science ®Google Scholar
• Mulakavalupil B, Vaity C, Joshi S, et al. Absence of case of mucormycosis (March 2020–May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit. Diabetes Metab Syndr. 2021;15(4):102169. doi:10.1016/j.dsx.2021.06.006
   PubMed Web of Science ®Google Scholar
• Leșan A, Man MA, Nemeș RM, et al. Serum interleukin 4 and 6 levels measured using the ELISA method in patients with acquired bronchiectasis compared to healthy subjects. An anti-inflammatory and pro-inflammatory relation. Rev Chim. 2019;70(7):2410–2414. doi:10.37358/RC.19.7.7351
   Web of Science ®Google Scholar
• Moțoc NS, Martinovici P, Mahler Boca B, et al. Neutrophil-to-lymphocyte ratio (NLR) and Platelets-to-lymphocyte (PLR) ratio in patients with exacerbation of bronchiectasis. Rev Chim Bucharest. 2019;70(11):3889–3892. doi:10.37358/RC.19.11.7665
   Web of Science ®Google Scholar
• Baghel SS, Keshri AK, Mishra P, et al. The spectrum of invasive fungal sinusitis in COVID-19 patients: experience from a tertiary care referral center in Northern India. J Fungi. 2022;8(3):223. doi:10.3390/jof8030223
   Web of Science ®Google Scholar
• Arora RD, Nagarkar NM, Krishna Sasanka KSBS, et al. Epidemic in pandemic: fungal sinusitis in COVID-19. J Family Med Prim Care. 2022;11(2):807–811. doi:10.4103/jfmpc.jfmpc_1352_21
   PubMedGoogle Scholar
• Samir A, Abdel-Gawad MS, Elabd AM, et al. Early CT and MRI signs of invasive fungal sinusitis complicating COVID-19 infection: case report. Egypt J Otolaryngol. 2022;38(1):17. doi:10.1186/s43163-022-00206-0
   Web of Science ®Google Scholar
• Pal R, Singh B, Bhadada SK, et al. COVID‐19‐associated mucormycosis: an updated systematic review of literature. Mycoses. 2021;64(12):1452–1459. PMID: 34133798; PMCID: PMC8447126. doi:10.1111/myc.13338
   PubMed Web of Science ®Google Scholar
• Nagalli S, Kikkeri NS. Mucormycosis in COVID-19: a systematic review of literature. Infez Med. 2021;29(4):504–512. PMID: 35146358; PMCID: PMC8805463. doi:10.53854/liim-2904-2
   PubMedGoogle Scholar
• Chakrabarti SS, Kaur U, Aggarwal SK, et al. The pathogenetic dilemma of post-COVID-19 mucormycosis in India. Aging Dis. 2022;13(1):24–28. PMID: 35111359; PMCID:PMC8782544. doi:10.14336/AD.2021.0811
   PubMedGoogle Scholar
• Gonzalez-Gronow M, Selim MA, Papalas J, Pizzo SV. GRP78: a multifunctional receptor on the cell surface. Antioxid Redox Signal. 2009;11:2299–2306. doi:10.1089/ars.2009.2568
   PubMed Web of Science ®Google Scholar
• Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: a cell’s response to stress. Life Sci. 2019;226:156–163. doi:10.1016/j.lfs.2019.04.022
   PubMed Web of Science ®Google Scholar
• Elfiky AA, Baghdady AM, Ali SA, Ahmed MI. GRP78 targeting: hitting two birds with a stone. Life Sci. 2020;260:118317. doi:10.1016/j.lfs.2020.118317
   PubMed Web of Science ®Google Scholar
• Sabirli R, Koseler A, Goren T, Turkcuer I, Kurt O. High GRP78 levels in Covid-19 infection: a case-control study. Life Sci. 2021;265:118781. doi:10.1016/j.lfs.2020.118781
   PubMed Web of Science ®Google Scholar
• Carlos AJ, Ha DP, Yeh D-W, et al. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection. J Biol Chem. 2021;296:100759. doi:10.1016/j.jbc.2021.100759
   PubMed Web of Science ®Google Scholar
• Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120:1914–1924. doi:10.1172/JCI42164
   PubMed Web of Science ®Google Scholar
• Visioli F, Wang Y, Alam GN, et al. Glucose-Regulated Protein 78 (Grp78) confers chemoresistance to tumor endothelial cells under acidic stress. PLoS One. 2014;9:e101053. doi:10.1371/journal.pone.0101053
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: analysis of cases from 18 countries (preprint) Lancet Microbe 2022;3(7):e543–e552. doi:10.1016/S2666-5247(21)00237-8
   PubMedGoogle Scholar
• Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, et al. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29–43. doi:10.1093/mmy/myx017
   PubMed Web of Science ®Google Scholar
• Aggarwal SK, Kaur U, Talda D, et al. Case report: rhino-orbital mucormycosis related to COVID-19: a case series exploring risk factors. Am J Trop Med Hyg. 2021;106(2):566–570. PMID: 34902834; PMCID: PMC8832906. doi:10.4269/ajtmh.21-0777
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinl Infect Dis. 2005;41(5):634–653. doi:10.1086/432579
   PubMed Web of Science ®Google Scholar
• Uğurlu ŞK, Selim S, Kopar A, et al. Rhino-orbital mucormycosis: clinical findings and treatment outcomes of four cases. Turk J Ophthalmol. 2015;45(4):169. doi:10.4274/tjo.82474
   PubMedGoogle Scholar